Last updated: February 23, 2026
What Is the Drug and Its Therapeutic Class?
NDC 64597-0301 corresponds to Zeposia (ozanimod), developed by Bristol-Myers Squibb. It is an oral sphingosine-1-phosphate (S1P) receptor modulator approved for multiple sclerosis (MS) treatment, specifically relapsing forms of MS (RRMS). Zeposia is among newer oral disease-modifying therapies (DMTs), competing with drugs like Gilenya (fingolimod), Aubagio (teriflunomide), and Mayzent (siponimod).
Current Market Size and Growth Drivers
Multiple Sclerosis Market Overview
- The global MS therapeutics market was valued at approximately USD 24.3 billion in 2022.
- Expected compounded annual growth rate (CAGR): 5.2% from 2023 to 2030 (Grand View Research, 2022).
- The U.S. accounts for around 50% of this market, influenced by early adoption, high drug costs, and increasing prevalence.
U.S. Multiple Sclerosis Prevalence
- Approximately 947,000 individuals diagnosed with MS as of 2022 (National Multiple Sclerosis Society).
- Female-to-male ratio: 3:1.
- Average annual treatment expenses per patient: USD 70,000.
Competitor Landscape
| Drug Name |
MoA |
Year Marketed |
Estimated Global Sales (2022) |
Market Share (2022) |
| Gilenya |
Fingolimod |
2010 |
USD 3.4 billion |
14% |
| Aubagio |
Teriflunomide |
2013 |
USD 1.2 billion |
5% |
| Mayzent |
Siponimod |
2019 |
USD 700 million |
3% |
| Zeposia |
Ozanimod |
2020 |
USD 250 million |
1% |
Market Position of Zeposia (Ozanimod)
Zeposia entered the MS market in 2020. Its early adoption remains modest compared to established drugs but benefits from an improved safety profile over fingolimod, with fewer cardiac and infection-related side effects.
Factors Supporting Market Penetration
- Oral administration route improves compliance.
- Favorable safety and tolerability profile.
- Expanding indications, including ulcerative colitis (approved 2023), increase potential market size.
Limitations
- Competition from established therapies.
- Limited clinician familiarity initially.
- Pricing strategies influence market penetration.
Price Projections
Current Pricing Landscape
- Average wholesale price (AWP) in the U.S.: USD 84,000 per year for a 28-day supply (based on 0.92 mg daily dose).
- Insurance reimbursement and patient co-payments vary, impacting net revenue.
Historical Pricing Trends
| Year |
Average Wholesale Price (USD) |
Notes |
| 2020 |
USD 84,000 |
Launch year, initial pricing remains stable |
| 2022 |
USD 84,000 |
No significant change, market stabilization |
Future Price Trends (2023–2030)
- Market maturity may prompt price stabilization or slight reductions (~2–3% annually).
- Volume growth driven by expanded indications and increased U.S. prevalence could offset price declines.
- Potential for tiered or negotiated pricing with payers, possibly reducing the effective price point by 10–20%.
- As competition intensifies, pricing pressures could lead to discounts, with discounts to providers reducing net prices by 15–25% compared to AWP.
Impact of New Indications and Formulations
- The expansion into ulcerative colitis broadens the revenue base, potentially allowing premium pricing in that segment.
- Oral formulations with comparable efficacy may push pricing downward over time.
Strategic Implications for Investors and R&D
- Market share growth depends on clinician adoption and payer negotiations.
- Near-term revenues are driven by existing MS patient populations, with long-term upside from expansion into related indications.
- Cost-pressure via biosimilars or generics remains unlikely for several years due to patent protections and brand loyalty.
Summary
| Aspect |
Key Data |
| Market Size (2022) |
USD 24.3 billion (global MS market) |
| Zeposia Sales (2022) |
USD 250 million |
| Pricing (2023) |
USD 84,000 per year (AWP) |
| Price Trend (2023–2030) |
Slight decline (~2–3% annually), evolving with competition and indications |
Key Takeaways
- Zeposia launched in a USD 24.3 billion MS market, holding a 1% share in 2022.
- Market growth driven by increasing prevalence, oral administration preference, and expanded indications.
- Price projections show stability initially, with slight declines anticipated due to market maturation and payer negotiations.
- Long-term potential hinges on expanding indications and market penetration against entrenched competitors.
FAQs
1. What is the competitive landscape for Zeposia?
Zeposia faces competition from Gilenya, Aubagio, and Mayzent. While Gilenya leads with a significant market share, Zeposia’s safety profile and new indications position it for gradual growth.
2. How might pricing evolve after 2023?
Pricing is expected to remain relatively stable or decline modestly (around 2–3%) annually, influenced by payer negotiations, competitive pressures, and expanded indications.
3. What factors could accelerate market share growth?
Increased clinician familiarity, favorable pricing strategies, expanded indications like ulcerative colitis, and demonstrated long-term safety could boost adoption.
4. Are there risks to Zeposia’s market expansion?
Yes. Competitive drugs may lower prices, and changes in payer policies could restrict access. Delays in clinical approvals for new indications pose additional risks.
5. How do patent protections affect future pricing?
Patent protections lasting until at least 2030 limit generic entry, supporting stable pricing and revenue. Patent expirations could introduce biosimilars or generics, impacting prices.
Citations:
[1] Grand View Research. (2022). Multiple Sclerosis Therapeutics Market Size, Share & Trends Analysis Report.
[2] National Multiple Sclerosis Society. (2022). MS Prevalence Data.
[3] Bristol-Myers Squibb. (2020). Zeposia (ozanimod) label & prescribing information.
